Beiley Biofund

Beiley Biofund Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Beiley Biofund (7882.TWO) as of Oct 27, 2026 is 225.82 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -640.86 % — a change of -135.24% (higher).

Cash Conversion

225.82 %

YoY

-135.24%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Beiley Biofund is 2024 225.82 % . Cash Conversion Rate (OCF/Net Income) of Beiley Biofund was 2023 -640.86 % . It decreases by -135.24% higher compared to the previous year.

The Beiley Biofund Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2023
-640.86 TWD
Jan 1, 2024
225.82 TWD
The Beiley Biofund Cash Conversion history
YEARCash ConversionYoY
225.82 %-135.24%
-640.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beiley Biofund Stock analysis

What does Beiley Biofund do? Beiley Biofund Inc generates revenue through venture capital investments in biotechnology and healthcare sectors. The company focuses on new drug and pharmaceutical R&D, advanced medical devices, pharmaceutical manufacturing, diagnostics, precision medicine, innovative medical service technologies, healthcare networks, and agricultural biotechnology. Its primary investment scope is domestic, targeting companies within Taiwan's biotech industry. The firm's revenue comes from capital gains and returns on its portfolio investments in these specialized areas. Beiley Biofund Inc operates as a Taiwan-based venture capital firm with a domestic investment focus. It targets biotechnology and healthcare companies developing innovative solutions in drug development, medical devices, and precision medicine. The firm's investment strategy centers on companies within Taiwan's biotech ecosystem, providing capital for growth and innovation. Revenue is derived from successful exits and equity appreciation in its portfolio companies. The company's investment areas include pharmaceutical manufacturing and services, diagnostics, precision medicine, and agricultural biotechnology. Beiley Biofund Inc concentrates on firms within Taiwan's domestic market, making capital available for biotech startups and established players. Revenue is generated through the financial performance of its investment portfolio in these specific sectors. Beiley Biofund is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beiley Biofund stock

Cash Conversion Rate (OCF/Net Income) of Beiley Biofund is 225.82 % in 2024.

Cash Conversion Rate (OCF/Net Income) of Beiley Biofund changed from -640.86 % to 225.82 %, representing a -135.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Beiley Biofund since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Beiley Biofund with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Beiley Biofund

All Key Metrics — Beiley Biofund